Vigilant Capital Management Exits Position in NuVasive (NUVA)

NuVasive (NUVA) : Vigilant Capital Management has sold out all of its stake in NuVasive during the most recent quarter, according to the disclosure filed by the company on Oct 14, 2016 with the SEC. The investment management company has sold out 65 shares of NuVasive which is valued at $4,264.

Other Hedge Funds, Including , Msi Financial Services Inc reduced its stake in NUVA by selling 50 shares or 51.02% in the most recent quarter. The Hedge Fund company now holds 48 shares of NUVA which is valued at $3,182.Capstone Asset Management Co reduced its stake in NUVA by selling 310 shares or 1.65% in the most recent quarter. The Hedge Fund company now holds 18,499 shares of NUVA which is valued at $1,225,559. NuVasive makes up approx 0.04% of Capstone Asset Management Co’s portfolio.Simplex Trading reduced its stake in NUVA by selling 1,848 shares or 79.45% in the most recent quarter. The Hedge Fund company now holds 478 shares of NUVA which is valued at $32,126.

NuVasive closed down -0.69 points or -1.04% at $65.6 with 2,92,032 shares getting traded on Friday. Post opening the session at $66.62, the shares hit an intraday low of $65.53 and an intraday high of $66.8703 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, NuVasive reported $0.31 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.27. The company had revenue of $215.10 million for the quarter, compared to analysts expectations of $205.44 million. The company’s revenue was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.30 EPS.

Many Wall Street Analysts have commented on NuVasive. Company shares were Reiterated by Barclays on Jul 27, 2016 to “Overweight”, Firm has raised the Price Target to $ 71 from a previous price target of $63 .

Nuvasive Inc. is a global medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its marketed product portfolio is focused on applications for spine fusion surgery. Its product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery provide visualization and are designed to enable reproducible outcomes for the surgeon and the patient. The platform includes the Company’s software-driven nerve detection and avoidance systems including NVM5 and NVJJB Intra-Operative Monitoring (IOM) services and support; MaXcess which is an integrated split-blade retractor system and a variety of implants and biologics.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

NuVasive - Is it time to Sell?

Top Brokerage Firms are advising their investors on NuVasive. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.